Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Enzastaurin · DB-102, LY-317615

Small molecule · Inhibitor of protein kinase C · developed by Eli Lilly and Company

Phase 3 Most advanced trial (none active)
1 Registered trials

What is Enzastaurin?

Enzastaurin is a serine threonine kinase inhibitor studied in non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate cancers, as well as vascular Ehlers-Danlos syndrome. It blocks cell signaling pathways and inhibits angiogenesis to prevent tumor growth.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DB-102, LY-317615
Drug type
Small molecule
Targets
protein kinase C
Mechanism
Inhibitor of protein kinase C
Pathways
angiogenesis
Therapy area
Cardiovascular, Dermatology, Hematology
Developer
Eli Lilly and Company
In trials of
AYTU
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
UC96G28EQF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05463679 Phase 3 Vascular Ehlers-Danlos Syndrome Suspended AYTU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Vascular Ehlers-Danlos Syndrome

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.